Esophageal cancer is the 6th most common cause of cancer related deaths which drives a need for a better understanding of the underlying mechanisms behind the disease through preclinical models. Patient derived xenograft (PDX) models provide a true representation of the human heterogeneity and can be used to better understand these mechanisms in relation to the development of new therapies. CrownBio has a large selection of well characterized Esophageal cancer PDX models, including models with EGFR amplification. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.